2024-07-15 13:54:02 ET
Summary
- Immutep Limited achieved positive results in the phase 2b study, using efti + Keytruda for the treatment of patients with 1st-line head and neck squamous cell carcinoma; Both PD-L1 positive and negative patients.
- Company to meet with FDA to be in a position to initiate a phase 3 study using efti + Keytruda for the treatment of patients with 1st-line HNSCC.
- Merck supply collaboration agreement in place to advance phase 3 study, using efti + Keytruda + chemotherapy for the treatment of 1stline NSCLC patients.
- Keytruda had become one of the top-selling drugs in 2023, with sales exceeding $25 billion; Efti has shown to help double several efficacy measures when added to Keytruda.
Immutep Limited ( IMMP ) recently reported results from two cohorts from its phase 2b TACTI-003 study using efti [eftilagimod alfa] for recurrent/metastatic 1st-line head and neck squamous cell carcinoma [HNSCC] patients. The first set of results was based on this entire patient population, regardless of PD-L1 expression. The other set of positive results released a few weeks later was based on this same patient population, but for such patients with negative PD-L1 expression. With this positive data on hand, this biotech is going to approach the FDA to get a phase 3 study going targeting one or both of these 1st-line HNSCC patient populations.
This is one program, which is already moving towards late-stage development. One other program, already underway in phase 3 testing, would be the phase 3 TACTI-004 trail. This specific late-stage study is using efti in combination with Keytruda + chemotherapy for the treatment of patients with 1st-line non-small cell lung cancer. Both of these programs are being done as a supply collaboration agreement with Merck ( MRK ), where this big pharma is providing supply of Keytruda to run these studies. Immutep still retains rights to efti for now....
Read the full article on Seeking Alpha
For further details see:
Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs